Lynd L. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework.

Sadatsafavi M, Marra C, Marra F, Moran O, Fitzgerald JM, Lynd L. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework. Value Health. 2013 Jan-Feb;16(1):66-75. doi: 10.1016/j.jval.2012.09.006. PMID: 23337217